Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia
暂无分享,去创建一个
N. Aaronson | M. Baccarani | S. Molica | M. Vignetti | F. Mandelli | G. Rosti | F. Cottone | E. Angelucci | F. Efficace
[1] G. Abel,et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24 , 2014, Quality of Life Research.
[2] C. Cleeland,et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. , 2013, Blood.
[3] H. Jim,et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison , 2013, Supportive Care in Cancer.
[4] G. Specchia,et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib , 2013, Leukemia.
[5] D. Marin. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[6] M. Baccarani,et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.
[7] M. Baccarani,et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. , 2011, Blood.
[8] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[9] D. Marin,et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. , 2011, Leukemia research.
[10] A. Nagler,et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.
[11] J. Cortes,et al. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia , 2011, Cancer.
[12] M. Gilbert,et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Ricardo Pasquini,et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.
[14] D. Marin,et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Ethan Basch,et al. The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.
[16] Alexia Iasonos,et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.
[17] Snootfull. not at all.... , 2009 .
[18] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[19] N. Aaronson,et al. Use of health‐related quality‐of‐life assessments in daily clinical oncology nursing practice , 2008, Cancer.
[20] Thomas R. Miller,et al. Self-Rated Health , 2008, Journal of aging and health.
[21] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[22] M. Kris,et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. , 2006, The Lancet. Oncology.
[23] M. Mori,et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Galina Velikova,et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Amadori,et al. Cancer‐related fatigue , 2003, Cancer.
[26] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[27] N. Aaronson,et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. , 2002, JAMA.
[28] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[29] M. Kris,et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .
[31] M. Suarez‐Almazor,et al. Lack of congruence in the ratings of patients' health status by patients and their physicians. , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] D. Osoba,et al. Assessing quality of life in clinical trials. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.